ZA200202655B - Hexahydrofuro[2,3-b]furan-3-yl-N-{3-[(1,3-benzodioxol -5-ylsulfonyl) (isobutyl) amino]-1-benzyl-2-hydroxypropyl} carbamate as retroviral protease inhibitor. - Google Patents

Hexahydrofuro[2,3-b]furan-3-yl-N-{3-[(1,3-benzodioxol -5-ylsulfonyl) (isobutyl) amino]-1-benzyl-2-hydroxypropyl} carbamate as retroviral protease inhibitor.

Info

Publication number
ZA200202655B
ZA200202655B ZA200202655A ZA200202655A ZA200202655B ZA 200202655 B ZA200202655 B ZA 200202655B ZA 200202655 A ZA200202655 A ZA 200202655A ZA 200202655 A ZA200202655 A ZA 200202655A ZA 200202655 B ZA200202655 B ZA 200202655B
Authority
ZA
South Africa
Prior art keywords
hexahydrofuro
ylsulfonyl
benzodioxol
furan
carbamate
Prior art date
Application number
ZA200202655A
Other languages
English (en)
Inventor
Piet Tom Bert Paul Wigerinck
Guangyang Wang
Michael Eissenstat
John W Erickson
Original Assignee
Tibotec Pharm Ltd
Nat Inst Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tibotec Pharm Ltd, Nat Inst Health filed Critical Tibotec Pharm Ltd
Publication of ZA200202655B publication Critical patent/ZA200202655B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
ZA200202655A 1999-10-06 2002-04-04 Hexahydrofuro[2,3-b]furan-3-yl-N-{3-[(1,3-benzodioxol -5-ylsulfonyl) (isobutyl) amino]-1-benzyl-2-hydroxypropyl} carbamate as retroviral protease inhibitor. ZA200202655B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US15785099P 1999-10-06 1999-10-06

Publications (1)

Publication Number Publication Date
ZA200202655B true ZA200202655B (en) 2003-09-23

Family

ID=22565540

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200202655A ZA200202655B (en) 1999-10-06 2002-04-04 Hexahydrofuro[2,3-b]furan-3-yl-N-{3-[(1,3-benzodioxol -5-ylsulfonyl) (isobutyl) amino]-1-benzyl-2-hydroxypropyl} carbamate as retroviral protease inhibitor.

Country Status (25)

Country Link
US (2) US6649651B1 (cs)
EP (1) EP1222192B8 (cs)
JP (1) JP4951179B2 (cs)
KR (1) KR100792391B1 (cs)
CN (1) CN1191256C (cs)
AP (1) AP1459A (cs)
AT (1) ATE398623T1 (cs)
AU (1) AU781656B2 (cs)
BR (1) BR0014602A (cs)
CA (1) CA2386850C (cs)
CZ (1) CZ300031B6 (cs)
DE (1) DE60039244D1 (cs)
DK (1) DK1222192T3 (cs)
ES (1) ES2307533T3 (cs)
HU (1) HU228938B1 (cs)
IL (2) IL149005A0 (cs)
MX (1) MXPA02003607A (cs)
NO (1) NO327996B1 (cs)
NZ (1) NZ518580A (cs)
OA (1) OA12053A (cs)
PL (1) PL204924B1 (cs)
RU (1) RU2247123C2 (cs)
SK (1) SK287153B6 (cs)
WO (1) WO2001025240A1 (cs)
ZA (1) ZA200202655B (cs)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU228938B1 (hu) * 1999-10-06 2013-06-28 Us Government Hexahidrofuro[2,3-b]furán-3-il-N-{3-(1,3-benzodioxol-5-il-szulfonil)-(izobutil)-amino-1-benzil-2- -(hidroxi-propil)}-karbamát mint retrovírus proteáz gátló
MXPA03009179A (es) * 2001-04-09 2004-11-22 Tibotec Pharm Ltd 2-(amino sustituido)-benzoxazol sunfonamidas, inhibidores de amplio espectro de la vih proteasa.
WO2003022853A1 (en) * 2001-09-10 2003-03-20 Tibotec Pharmaceuticals Ltd. Method for the preparation of hexahydro-furo[2,3-b]furan-3-ol
WO2003057173A2 (en) * 2002-01-07 2003-07-17 Sequoia Pharmaceuticals Broad spectrum inhibitors
US7285566B2 (en) * 2002-01-07 2007-10-23 Erickson John W Resistance-repellent retroviral protease inhibitors
US7157489B2 (en) * 2002-03-12 2007-01-02 The Board Of Trustees Of The University Of Illinois HIV protease inhibitors
IL165043A0 (en) 2002-05-17 2005-12-18 Tibotec Pharm Ltd broadspectrum substituted benzisoxazole sulfonamide hiv protease inhibitors
JP4879484B2 (ja) * 2002-08-02 2012-02-22 テイボテク・フアーマシユーチカルズ・リミテツド 広スペクトルの２−アミノ−ベンゾチアゾールスルホンアミドｈｉｖプロテアーゼ阻害剤
EP1589018A4 (en) 2002-12-27 2007-03-14 Sumitomo Chemical Co METHOD OF PREPARING HEXAHYDROFUROFURANOL DERIVATIVES, INTERMEDIATE PRODUCTS AND MANUFACTURING METHOD THEREFOR
US7807845B2 (en) * 2004-03-11 2010-10-05 Sequoia Pharmaceuticals, Inc. Resistance-repellent retroviral protease inhibitors
TWI383975B (zh) 2004-03-31 2013-02-01 悌柏泰克醫藥有限公司 製備（３Ｒ，３ａＳ，６ａＲ）六氫-呋喃并〔２，３-ｂ〕呋喃-３-醇之方法
KR100698291B1 (ko) * 2004-12-29 2007-03-22 엘지전자 주식회사 조명계
RU2421459C2 (ru) 2005-02-25 2011-06-20 Тиботек Фармасьютикалз Лтд. Синтез предшественника ингибитора протеазы
FR2888849B1 (fr) * 2005-07-19 2007-10-05 Pierre Fabre Medicament Sa Procede de preparation de la 4b-amino-4'-demethyl-4-desoxypodophyllotoxine
CN103275033B (zh) 2006-07-07 2015-04-29 吉里德科学公司 治疗剂的药代动力学特性调节剂
US20090312318A1 (en) * 2006-07-24 2009-12-17 Desai Manoj C Therapeutic compounds and methods
DE602007012365D1 (de) 2006-11-09 2011-03-17 Little Island Co Cork Verfahren zur herstellung von hexahydrofuroä2,3-büfuran-3-ol
US9808527B2 (en) 2006-11-21 2017-11-07 Purdue Research Foundation Methods and compositions for treating HIV infections
AP2986A (en) 2007-02-23 2014-09-30 Gilead Sciences Inc Modulators of pharmacokinetic properties of therapeutics
EP2134336B1 (en) 2007-03-16 2013-12-11 Sequoia Pharmaceuticals Benzofuran-derived hiv protease inhibitors
JP5393665B2 (ja) 2007-07-06 2014-01-22 ギリアード サイエンシーズ， インコーポレイテッド 治療剤の薬物動態特性の調整剤
CA2710679A1 (en) 2008-01-04 2009-07-16 Gilead Sciences, Inc. Inhibitors of cytochrome p450
WO2009091941A1 (en) 2008-01-17 2009-07-23 Purdue Research Foundation Small molecule inhibitors of hiv proteases
EP2307345A4 (en) 2008-07-01 2012-05-02 Purdue Research Foundation NON-PEPTIDINHIBITORS OF HIV-1 PROTEASE
US8501961B2 (en) 2008-07-09 2013-08-06 Purdue Research Foundation HIV protease inhibitors and methods for using
ES2600878T3 (es) 2009-12-21 2017-02-13 Janssen Sciences Ireland Uc Implante removible, degradable, para la liberación prolongada de un compuesto activo
PL2643326T3 (pl) 2010-11-23 2017-06-30 Mylan Laboratories, Limited Sposób przygotowania (3R, 3aS, 6aR)-heksahydrofuro[2,3-b]furan-3-olu
EP2883858B1 (en) * 2012-08-09 2017-12-27 Sumitomo Chemical Company Limited Method for producing hexahydrofurofuranol derivative
CN103664976B (zh) * 2013-12-12 2015-11-04 惠州市莱佛士制药技术有限公司 一种顺式六氢呋喃并[2,3-b]呋喃-3-醇的制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE154800T1 (de) * 1992-08-25 1997-07-15 Searle & Co N-(alkanoylamino-2-hydroxypropyl)-sulfonamide verwendbar als retrovirale proteaseninhibitoren
CA2140929C (en) * 1992-08-25 2006-09-12 Michael L. Vazquez Hydroxyethylamino sulfonamides useful as retroviral protease inhibitors
US5723490A (en) * 1992-09-08 1998-03-03 Vertex Pharmaceuticals Incorporated THF-containing sulfonamide inhibitors of aspartyl protease
IS2334B (is) * 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl próteasi hemjari af nýjum flokki súlfonamíða
ATE174587T1 (de) 1993-08-24 1999-01-15 Searle & Co Hydroxyaminosulfonamide verwendbar als inhibitoren retroviraler proteasen
UA49803C2 (uk) * 1994-06-03 2002-10-15 Дж.Д. Сьорль Енд Ко Спосіб лікування ретровірусних інфекцій
US5705500A (en) * 1995-03-10 1998-01-06 G.D. Searle & Co. Sulfonylalkanoylamino hydroxyethylamino sulfonamide retroviral protease inhibitors
US5691372A (en) * 1995-04-19 1997-11-25 Vertex Pharmaceuticals Incorporated Oxygenated-Heterocycle containing sulfonamide inhibitors of aspartyl protease
AU771780B2 (en) 1998-06-23 2004-04-01 Board Of Trustees Of The University Of Illinois, The Fitness assay and associated methods
AU4828199A (en) 1998-06-23 2000-01-10 Board Of Trustees Of The University Of Illinois, The Multi-drug resistant retroviral protease inhibitors and associated methods
GB9815567D0 (en) * 1998-07-18 1998-09-16 Glaxo Group Ltd Antiviral compound
HU228938B1 (hu) * 1999-10-06 2013-06-28 Us Government Hexahidrofuro[2,3-b]furán-3-il-N-{3-(1,3-benzodioxol-5-il-szulfonil)-(izobutil)-amino-1-benzil-2- -(hidroxi-propil)}-karbamát mint retrovírus proteáz gátló

Also Published As

Publication number Publication date
US7157495B2 (en) 2007-01-02
IL149005A0 (en) 2002-11-10
CN1191256C (zh) 2005-03-02
DK1222192T3 (da) 2008-10-20
CA2386850C (en) 2010-03-30
SK287153B6 (sk) 2010-01-07
JP4951179B2 (ja) 2012-06-13
HUP0203130A3 (en) 2005-01-28
JP2003511383A (ja) 2003-03-25
SK5702002A3 (en) 2003-01-09
BR0014602A (pt) 2002-06-11
AP2002002472A0 (en) 2002-06-30
KR20020067503A (ko) 2002-08-22
RU2247123C2 (ru) 2005-02-27
US6649651B1 (en) 2003-11-18
AU781656B2 (en) 2005-06-02
CN1407987A (zh) 2003-04-02
HK1054746A1 (en) 2003-12-12
CA2386850A1 (en) 2001-04-12
HU228938B1 (hu) 2013-06-28
EP1222192B1 (en) 2008-06-18
NO20021598L (no) 2002-05-29
NO20021598D0 (no) 2002-04-04
WO2001025240A1 (en) 2001-04-12
CZ20021419A3 (cs) 2002-10-16
ES2307533T3 (es) 2008-12-01
EP1222192B8 (en) 2008-10-01
IL149005A (en) 2006-12-31
PL354351A1 (en) 2004-01-12
DE60039244D1 (de) 2008-07-31
PL204924B1 (pl) 2010-02-26
AU7663800A (en) 2001-05-10
KR100792391B1 (ko) 2008-01-08
EP1222192A1 (en) 2002-07-17
MXPA02003607A (es) 2003-07-28
ATE398623T1 (de) 2008-07-15
HUP0203130A2 (hu) 2003-01-28
CZ300031B6 (cs) 2009-01-14
AP1459A (en) 2005-08-22
NO327996B1 (no) 2009-11-02
OA12053A (en) 2006-05-02
US20050261364A1 (en) 2005-11-24
NZ518580A (en) 2004-01-30

Similar Documents

Publication Publication Date Title
ZA200202655B (en) Hexahydrofuro[2,3-b]furan-3-yl-N-{3-[(1,3-benzodioxol -5-ylsulfonyl) (isobutyl) amino]-1-benzyl-2-hydroxypropyl} carbamate as retroviral protease inhibitor.
WO1999064047A8 (en) Novel antiviral compounds
ZA200107496B (en) Amine derivatives as protease inhitors.
ZA992447B (en) Quinoxalinones as serine protease inhibitors.
ZA200000075B (en) Enzymes mixture.
ZA200204283B (en) Novel antidiabetic agents.
ZA992344B (en) Game machine.
ZA200107096B (en) Woodworking jig.
ZA991551B (en) 6,9-Disubstituted 2-[trans-(4-aminocyclohexyl) amino] purines.
ZA200407817B (en) 2-(2,6-Dichlorophenyl)-diarylimidazoles.
ZA200004319B (en) Game machine.
ZA992448B (en) Quinoxalinones as serine protease inhibitors.
ZA991548B (en) 6,9-Disubstituted 2-[trans-(4-Aminocyclohexyl) Amino] Purines.
ZA992445B (en) Benzoxazinones/benzothiazinones as serine protease inhibitors.
ZA200004373B (en) Game machine.
ZA200007631B (en) Hand-held environmental monitor.
ZA99873B (en) Novel dihydroxyhexanoic acid derivatives.
ZA991268B (en) Novel sulfonamides.
HK1042036A1 (zh) 钙溶解化合物
ZA978552B (en) Retroviral protease inhibiting compounds.
MXPA03001783A (es) N-(3,5-dicloro-2-metoxifenil)-4-metoxi-3- piperazin-1 -il -bencenosulfonamida.
WO2001007408A3 (fr) Nouveau procede de preparation de composes benzoperhydroisoindole
ZA992214B (en) Oligomeric stabilizer mixture.
IL158033A0 (en) 3, 7-diazabicyclo [3.3.1] formulations as anti-arrhythmic compounds
MXPA02000261A (es) Aminoindanos novedosos.